IRIDEX Glaucoma Probe Volume Hits Record as Retina Sales Slip

IRIDEX said on its fiscal Q2 2026 earnings call that Cyclo-G6 glaucoma revenue rose 35% and probe volume hit a record while total revenue fell 7% on retina weakness, and the company reaffirmed full-year guidance and reported positive cash flow; IRIX traded at 0.72, down 22.73%, as of 13:45 GMT on 19 August 2026.

IRIDEX Corp (NASDAQ: IRIX) used its fiscal second-quarter 2026 earnings call to make a simple argument: the part of the business it wants investors to value is growing fast, and the part that is shrinking matters less every quarter. The company said revenue from its Cyclo-G6 glaucoma platform rose 35%, probe volume set a record, and it generated positive cash flow. Total revenue still fell 7%, held back by weakness in its retina products, and management reaffirmed full-year guidance anyway.

The market did not read it kindly. IRIX changed hands at 0.72 as of 13:45 GMT on 19 August 2026, down 22.73% from the prior close of 0.93, with a day range of 0.70 to 0.83. That happened on a session in which the broad market was mildly positive: the S&P 500 tracker (SPY) was at $770.11, up 0.35%, the Nasdaq 100 tracker (QQQ) at $718.13, up 0.09%, and the Dow tracker (DIA) at $534.44, up 0.29%. Whatever moved the stock, it was company-specific, and it was severe.

Two businesses pulling in opposite directions

IRIDEX sells laser systems and single-use probes into ophthalmology. The commercial logic of Cyclo-G6 is the razor-and-blade model that medical device investors tend to pay up for: place a console with a surgeon, then earn recurring revenue every time a disposable probe is used on a glaucoma patient. Growth of 35% in that franchise, paired with a record probe count, is the cleanest evidence available that the installed base is being used more intensively rather than merely sitting in clinics.

The retina side is the drag. IRIDEX described retina headwinds as the reason total revenue declined 7%, which tells you the direction but not the mechanics. Retina laser purchases are capital equipment decisions made by hospitals and practices, and capital equipment is the first line item that gets deferred when budgets tighten or when a product cycle turns over. Probes, by contrast, are consumed per procedure and track patient volume rather than purchasing committees.

The arithmetic of a mix shift like this is unforgiving in the short run and favourable later. A fast-growing consumables line has to get large enough in absolute terms to outrun a declining equipment line before the consolidated top line turns positive. IRIDEX has not reached that crossover point this quarter — the 7% decline says so — but the shape of the business at the crossover is materially better than the shape of it today.

Why reaffirmed guidance is the pressure point

Reaffirming full-year guidance after a revenue decline is a statement that management believes the shortfall is timing, not trend. That is a testable claim. If retina softness reflects deferred equipment orders, those orders reappear in the second half and guidance holds. If it reflects competitive displacement or a structural fall in retina procedure volumes, the same guidance becomes a hostage that has to be released later in the year.

The share price reaction suggests investors are weighting the second interpretation, or at least demanding to see the second half before paying for it. A 22.73% single-day decline in a sub-dollar stock is not a rounding error in sentiment; it is a repricing of how much credit the market extends to the glaucoma growth story while total revenue is still contracting.

Positive cash flow is the counterweight, and for a company of this size it is the most consequential detail on the call. Small-cap medical device names that burn cash face a recurring dilution problem: every quarter of negative cash flow is a future equity raise, and at a share price under a dollar, raising equity is expensive and unpopular with existing holders. Crossing into positive cash flow, even temporarily, changes the financing conversation. It is the difference between funding growth from operations and funding it from the market.

What the probe number actually signals

Record probe volume is worth separating from the 35% revenue figure, because the two can move for different reasons. Revenue growth can come from price, from mix, or from units. A record unit count alongside 35% growth points to genuine adoption — more procedures performed with the device, by more surgeons, more often. That is the metric that compounds, because a surgeon who has integrated a technique into routine practice tends not to reverse the decision.

For clinicians and health systems, the read-through is about where glaucoma treatment is heading. Laser-based approaches sit between drops and more invasive surgery, and utilisation data of this kind is one of the few public signals of how quickly that middle ground is being occupied. For suppliers and distributors, rising probe volume means the aftermarket, not the console sale, is where the margin story lives.

What to watch through the rest of the fiscal year

Three things will decide whether the current price is a mispricing or a warning. First, whether Cyclo-G6 growth holds anywhere near the reported 35% rate as the comparison base gets harder — deceleration would remove the single pillar supporting the guidance reaffirmation. Second, whether retina revenue stabilises or keeps falling; a second consecutive quarter of the same headwind would make the 7% consolidated decline look like a floor rather than a blip. Third, whether positive cash flow persists. One quarter is a data point; two is a trend, and it is the trend that determines whether IRIDEX needs outside capital.

The call details were reported by GuruFocus. What the company has offered is a coherent story about a business in transition; what it has not yet offered is a quarter in which the growth engine is large enough to lift the whole company. Until that arrives, the guidance reaffirmation is the load-bearing element of the investment case, and the market has priced it accordingly.

Frequently asked questions

What did IRIDEX report for fiscal Q2 2026?

IRIDEX reported that revenue from its Cyclo-G6 glaucoma platform rose 35% and that glaucoma probe volume reached a record level. Total company revenue fell 7%, which management attributed to headwinds in its retina business. The company also said it achieved positive cash flow and reaffirmed its full-year guidance on the earnings call.

Why did IRIX shares fall so sharply?

IRIX traded at 0.72 as of 13:45 GMT on 19 August 2026, down 22.73% from the prior close of 0.93. The decline came on a day when major US index trackers were modestly higher, so the move was company-specific. Investors appeared to focus on the 7% total revenue decline rather than the glaucoma growth.

What is Cyclo-G6 and why does it matter to IRIDEX?

Cyclo-G6 is IRIDEX's laser platform used in glaucoma treatment. It follows a razor-and-blade commercial model: the company places a console with a surgeon and then earns recurring revenue from single-use probes consumed during each procedure. Recurring consumable revenue is generally valued more highly than one-off capital equipment sales.

What are the retina headwinds IRIDEX cited?

IRIDEX said retina weakness drove its 7% total revenue decline but the lead does not specify the mechanics. Retina laser systems are capital equipment purchases made by hospitals and practices, and such purchases are commonly deferred when budgets tighten or a product cycle turns, in contrast to per-procedure consumables.

Is the reaffirmed full-year guidance credible?

Reaffirming guidance after a revenue decline implies management sees the shortfall as timing rather than trend. That is testable: if deferred retina equipment orders return in the second half, guidance can hold. If the weakness is structural or competitive, the reaffirmation becomes harder to defend later in the fiscal year.

Why does positive cash flow matter for a company this size?

For a small-cap device company trading below a dollar, negative cash flow implies future equity raises that dilute existing shareholders at unattractive prices. Reaching positive cash flow shifts growth funding from the capital markets to operations. One quarter is a data point; sustained positive cash flow would materially change the financing outlook.

Sources

• IRIDEX Corp (IRIX) (Q2 2026) Earnings Call Highlights: Cyclo-G6 Surges 35% as Company Achieves ... — GuruFocus

Photo: Pavel Danilyuk · Pexels Licence — source